.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Fuji
Harvard Business School
AstraZeneca
Cantor Fitzgerald
Citi
UBS
Chubb
Express Scripts

Generated: November 19, 2017

DrugPatentWatch Database Preview

Crisaborole - Generic Drug Details

« Back to Dashboard

What are the generic sources for crisaborole and what is the scope of crisaborole freedom to operate?

Crisaborole
is the generic ingredient in one branded drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Crisaborole has one hundred and six patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for crisaborole

Pharmacology for crisaborole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Anacor Pharms Inc
EUCRISA
crisaborole
OINTMENT;TOPICAL207695-001Dec 14, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: crisaborole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,440,642Boron-containing small molecules► Subscribe
9,029,353Boron-containing small molecules as anti-inflammatory agents► Subscribe
7,582,621Boron-containing small molecules► Subscribe
9,353,133Boron-containing small molecules► Subscribe
9,566,289Boron-containing small molecules► Subscribe
9,572,823Boron-containing small molecules► Subscribe
8,115,026Boron-containing small molecules► Subscribe
8,722,917Boron-containing small molecules► Subscribe
9,566,290Boron-containing small molecules► Subscribe
7,767,657Boron-containing small molecules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: crisaborole

Country Document Number Estimated Expiration
Japan2016199561► Subscribe
Spain2542342► Subscribe
China103479654► Subscribe
China105949230► Subscribe
Japan2013253097► Subscribe
Israel193230► Subscribe
Russian Federation2010133524► Subscribe
European Patent Office2719388► Subscribe
South Africa200806754► Subscribe
Mexico335993► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Chinese Patent Office
Farmers Insurance
Healthtrust
Moodys
QuintilesIMS
Daiichi Sankyo
Baxter
Cipla
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot